Spyre Therapeutics, Inc. (SYRE)
Develops antibody drugs to treat inflammatory bowel disease and rheumatic diseases.
$99.53-0.01%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+512.1%
The outlook
Spyre Therapeutics trades near its 52-week highs with uniform analyst enthusiasm—all 15 covering analysts rate it Strong Buy. The stock sits above both its 50- and 200-day moving averages, reflecting an uptrend. The average analyst price target sits about 4% above the current price.
What’s behind the score
Analyst consensusStrong Buy — 1.0 avg of 15 analysts
Price trendAbove its 50- & 200-day averages
52-week range94% of the way from its 52-week low to high
Price targetAvg target +4% vs current price
Analyst price target
~12-month · 15 analysts$103.93average target+4.4% vs now
Now $99.53
Low $78.00High $135.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$8.64B
52-wk high
$105.09
52-wk low
$14.51
50-day avg
$85.45
200-day avg
$50.78
Trailing P/E
—